
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics Inc. has demonstrated a substantial increase in year-over-year revenue growth, with 4,954 CNS reflecting a 57% increase, aided by a higher mix of new patient starts (NPS) in the pharmacy channel. The company has raised its revenue estimates for 2025 and 2026 to $97.5 million and $136 million respectively, indicating a strong operational performance and a positive outlook for future growth. Additionally, the robust performance in 4Q25, supported by strong new prescription momentum and effective expansion efforts in sales territories, reinforces confidence in Beta Bionics's potential to maintain its premium growth profile with a projected compound annual growth rate (CAGR) of 30-40% through 2028.
Bears say
Beta Bionics Inc faces several fundamental challenges that may negatively impact its stock outlook. First, the company's ability to capture meaningful market share with the iLet Bionic Pancreas is in jeopardy due to competitive pressures and potential difficulties in penetrating the pharmacy channel effectively, which could depress revenue and profitability estimates. Additionally, the need for further capital to support growth initiatives raises concerns about shareholder dilution, compounded by regulatory risks and unfavorable Medicare reimbursement proposals that could hinder market adoption and overall financial performance.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares